• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

局部晚期直肠癌预后不良的独立预测因子：甲酰肽受体 1（FPR1）中的 rs867228。

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1).

机构信息

Laboratory of Precision Medicine, Ministry of Health & Welfare Feng Yuan Hospital, Taichung, Taiwan.

Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.

出版信息

Oncoimmunology. 2021 May 14;10(1):1926074. doi: 10.1080/2162402X.2021.1926074.

DOI:10.1080/2162402X.2021.1926074
PMID:34026338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8128175/
Abstract

Formyl peptide receptor 1 (FPR1) plays a key regulatory role in innate and adaptive immunity. Recently, we reported that the CC genotype of FPR1-E346A (rs867228, c. 1037 A > C) is an independent biomarker for patients with locally advanced rectal cancer (LARC) who received preoperative concurrent chemoradiotherapy (CCRT). Pharmacologic inhibition of FPR1 decreased the migration and infiltration of T lymphocytes into tumor microenvironment after CCRT.

摘要

甲酰肽受体 1（FPR1）在先天免疫和适应性免疫中发挥关键的调节作用。最近，我们报道 FPR1-E346A（rs867228，c.1037 A > C）的 CC 基因型是接受术前同期放化疗（CCRT）的局部晚期直肠癌（LARC）患者的独立生物标志物。FPR1 的药理学抑制作用可降低 CCRT 后 T 淋巴细胞向肿瘤微环境的迁移和浸润。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e005/8128175/d2524803f063/KONI_A_1926074_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e005/8128175/d2524803f063/KONI_A_1926074_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e005/8128175/d2524803f063/KONI_A_1926074_F0001_OC.jpg

相似文献

1
An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1).局部晚期直肠癌预后不良的独立预测因子：甲酰肽受体 1（FPR1）中的 rs867228。
Oncoimmunology. 2021 May 14;10(1):1926074. doi: 10.1080/2162402X.2021.1926074.
2
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.形式肽受体 1（FPR1）多态性降低了局部晚期直肠癌新辅助放化疗（CCRT）治疗后的治疗效果和抗肿瘤免疫。
Cancer Immunol Immunother. 2021 Oct;70(10):2937-2950. doi: 10.1007/s00262-021-02894-8. Epub 2021 Mar 13.
3
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis.甲酰肽受体 1（FPR1）抑制肠道肿瘤发生。
Oncoimmunology. 2023 Jul 21;12(1):2237354. doi: 10.1080/2162402X.2023.2237354. eCollection 2023.
4
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer.FPR1 上的 rs867228 加速了管腔 B 型乳腺癌的发生。
Oncoimmunology. 2023 Mar 21;12(1):2189823. doi: 10.1080/2162402X.2023.2189823. eCollection 2023.
5
No impact of cancer and plague-relevant polymorphisms on COVID-19.癌症和瘟疫相关多态性对 COVID-19 无影响。
Oncoimmunology. 2020 Dec 8;9(1):1857112. doi: 10.1080/2162402X.2020.1857112.
6
Impact of Pattern Recognition Receptors on the Prognosis of Chemotherapy-treated Rectal Cancer Patients.模式识别受体对化疗治疗直肠癌患者预后的影响。
In Vivo. 2023 Jul-Aug;37(4):1552-1561. doi: 10.21873/invivo.13240.
7
[Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].[MLH3和MSH2基因的遗传变异与接受术前放化疗的局部晚期直肠癌患者的敏感性和预后相关]
Zhonghua Zhong Liu Za Zhi. 2018 Jun 23;40(6):433-440. doi: 10.3760/cma.j.issn.0253-3766.2018.06.007.
8
Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.靶向甲酰肽受体 1 以防止卵巢癌细胞黏附到间皮并随后侵袭。
J Exp Clin Cancer Res. 2019 Nov 8;38(1):459. doi: 10.1186/s13046-019-1465-8.
9
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.靶向尿激酶受体和甲酰肽受体 1 之间的串扰以防止黑色素瘤细胞的侵袭和跨内皮迁移。
J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x.
10
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.化疗诱导的抗肿瘤免疫需要甲酰肽受体 1。
Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.

引用本文的文献

1
Identification of a necroptosis-related gene signature for making clinical predictions of the survival of patients with lung adenocarcinoma.鉴定一个与细胞坏死性凋亡相关的基因特征，用于对肺腺癌患者的生存进行临床预测。
PeerJ. 2024 Jan 8;12:e16616. doi: 10.7717/peerj.16616. eCollection 2024.
2
Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.基于 bulk RNA-seq 和单细胞 RNA-seq 的高级别浆液性卵巢癌中单核细胞相关预后模型的构建。
Medicine (Baltimore). 2023 Dec 15;102(50):e36548. doi: 10.1097/MD.0000000000036548.
3

本文引用的文献

1
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.形式肽受体 1（FPR1）多态性降低了局部晚期直肠癌新辅助放化疗（CCRT）治疗后的治疗效果和抗肿瘤免疫。
Cancer Immunol Immunother. 2021 Oct;70(10):2937-2950. doi: 10.1007/s00262-021-02894-8. Epub 2021 Mar 13.
2
Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm.局部晚期直肠癌的个性化治疗：将病理、分子遗传和免疫生物标志物纳入多模式治疗模式
Front Oncol. 2020 Aug 14;10:1369. doi: 10.3389/fonc.2020.01369. eCollection 2020.
3
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis.
甲酰肽受体 1（FPR1）抑制肠道肿瘤发生。
Oncoimmunology. 2023 Jul 21;12(1):2237354. doi: 10.1080/2162402X.2023.2237354. eCollection 2023.
4
Trial watch: chemotherapy-induced immunogenic cell death in oncology.研究动态：肿瘤治疗中的化疗诱导免疫原性细胞死亡
Oncoimmunology. 2023 Jun 3;12(1):2219591. doi: 10.1080/2162402X.2023.2219591. eCollection 2023.
5
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer.FPR1 上的 rs867228 加速了管腔 B 型乳腺癌的发生。
Oncoimmunology. 2023 Mar 21;12(1):2189823. doi: 10.1080/2162402X.2023.2189823. eCollection 2023.
6
Annexin-A1: The culprit or the solution?膜联蛋白A1：罪魁祸首还是解决方案？
Immunology. 2022 May;166(1):2-16. doi: 10.1111/imm.13455. Epub 2022 Mar 1.
The ambiguous role of FPR1 in immunity and inflammation.FPR1在免疫和炎症中的模糊作用。
Oncoimmunology. 2020 Apr 30;9(1):1760061. doi: 10.1080/2162402X.2020.1760061. eCollection 2020.
4
Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells.放疗引发抗肿瘤免疫：垂死肿瘤细胞衍生的损伤相关分子模式触发内皮细胞活化和髓样细胞募集。
Oncoimmunology. 2018 Nov 2;8(1):e1523097. doi: 10.1080/2162402X.2018.1523097. eCollection 2019.
5
Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.肿瘤微环境中的细胞质高迁移率族蛋白 B1（HMGB1）和/或 PD-1+TILs 可能是接受新辅助放化疗的局部晚期直肠癌患者的预后生物标志物。
Cancer Immunol Immunother. 2018 Apr;67(4):551-562. doi: 10.1007/s00262-017-2109-5. Epub 2017 Dec 21.
6
Damage-associated molecular patterns in cancer: a double-edged sword.癌症中的损伤相关分子模式：一把双刃剑。
Oncogene. 2016 Nov 17;35(46):5931-5941. doi: 10.1038/onc.2016.104. Epub 2016 Apr 18.
7
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.化疗诱导的抗肿瘤免疫需要甲酰肽受体 1。
Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.
8
The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.甲酰化肽和甲酰肽受体1在急性炎症期间调控中性粒细胞功能中的作用。
Am J Pathol. 2015 May;185(5):1172-84. doi: 10.1016/j.ajpath.2015.01.020. Epub 2015 Mar 17.
9
Antitumor immune responses induced by ionizing irradiation and further immune stimulation.电离辐射诱导的抗肿瘤免疫反应及进一步的免疫刺激。
Cancer Immunol Immunother. 2014 Jan;63(1):29-36. doi: 10.1007/s00262-013-1474-y. Epub 2013 Sep 20.
10
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.局部进展期直肠癌术前与术后放化疗的比较：中位随访 11 年后德国 CAO/ARO/AIO-94 随机 III 期临床试验结果。
J Clin Oncol. 2012 Jun 1;30(16):1926-33. doi: 10.1200/JCO.2011.40.1836. Epub 2012 Apr 23.